Patients with high‐risk differentiated thyroid cancer have a lower I‐131 ablation success rate than low‐risk ones in spite of a high ablation activity

To examine success rates in strictly defined high‐risk differentiated thyroid cancer (DTC) patients who received a high‐activity (≥5550 MBq) adjuvant postoperative I‐131 therapy and compare these to the rates found in highest risk and low‐risk patients.

[1]  M. Luster,et al.  The absorbed dose to the blood is a better predictor of ablation success than the administered 131I activity in thyroid cancer patients , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[2]  S. Mandel,et al.  2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[3]  G. Pentheroudakis,et al.  Thyroid cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  F. Verburg,et al.  The success rate of 131 I ablation in thyroid cancer patients is significantly reduced after a diagnostic activity of 40 MBq 131 I , 2009 .

[5]  Richard A. Szucs,et al.  TNM Classification of Malignant Tumors. 5th ed , 1998 .

[6]  M. Stokkel,et al.  The success of 131I ablation in thyroid cancer patients is significantly reduced after a diagnostic activity of 40 MBq 131I , 2009, Nuklearmedizin.

[7]  F. Pitoia,et al.  Radioiodine Thyroid Remnant Ablation after Recombinant Human Thyrotropin or Thyroid Hormone Withdrawal in Patients with High-Risk Differentiated Thyroid Cancer , 2012, Journal of thyroid research.

[8]  A. Haug,et al.  High-risk patients with differentiated thyroid cancer T4 primary tumors achieve remnant ablation equally well using rhTSH or thyroid hormone withdrawal. , 2014, Thyroid : official journal of the American Thyroid Association.

[9]  A. Buck,et al.  The number of 131I therapy courses needed to achieve complete remission is an indicator of prognosis in patients with differentiated thyroid carcinoma , 2014, European Journal of Nuclear Medicine and Molecular Imaging.

[10]  A. Bockisch,et al.  The influence of saliva flow stimulation on the absorbed radiation dose to the salivary glands during radioiodine therapy of thyroid cancer using 124I PET(/CT) imaging , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[11]  M. Luster,et al.  Impact of 131I diagnostic activities on the biokinetics of thyroid remnants. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[12]  C. Reiners,et al.  Long-term survival in differentiated thyroid cancer is worse after low-activity initial post-surgical 131I therapy in both high- and low-risk patients. , 2014, The Journal of clinical endocrinology and metabolism.

[13]  M. Luster,et al.  No survival difference after successful 131I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer , 2010, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  B. de Keizer,et al.  Prognostic significance of successful ablation with radioiodine of differentiated thyroid cancer patients. , 2005, European journal of endocrinology.

[15]  M. Gapany.  No survival difference after successful 131I ablation between patients with initially low-risk and high-risk differentiated thyroid cancer , 2011 .

[16]  Stephanie L. Lee,et al.  Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. , 2009, Thyroid : official journal of the American Thyroid Association.

[17]  P. Rosário,et al.  Recombinant human thyrotropin in thyroid remnant ablation with 131-iodine in high-risk patients. , 2010, Thyroid : official journal of the American Thyroid Association.

[18]  M. Ranney,et al.  Beyond the bedside: Clinicians as guardians of public health, medicine and science , 2020, The American Journal of Emergency Medicine.

[19]  S. Larson,et al.  Recombinant Human TSH–Assisted Radioactive Iodine Remnant Ablation Achieves Short-Term Clinical Recurrence Rates Similar to Those of Traditional Thyroid Hormone Withdrawal , 2008, Journal of Nuclear Medicine.

[20]  B. Weintraub,et al.  A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer. , 1999, The Journal of clinical endocrinology and metabolism.

[21]  L. Duntas,et al.  Implications of thyroglobulin antibody positivity in patients with differentiated thyroid cancer: a clinical position statement. , 2013, Thyroid : official journal of the American Thyroid Association.

[22]  Kaliszewski,et al.  American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer : The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer , 2017 .

[23]  L. Sobin,et al.  TNM Classification of Malignant Tumours , 1987, UICC International Union Against Cancer.

[24]  C. Reiners,et al.  Procedure guideline for iodine-131 whole-body scintigraphy for differentiated thyroid cancer (version 2) , 2003, Nuklearmedizin.

[25]  C. Reiners,et al.  Success of the postoperative 131I therapy in young Belarusian patients with differentiated thyroid cancer after Chernobyl depends on the radiation absorbed dose to the blood and the thyroglobulin level , 2011, European Journal of Nuclear Medicine and Molecular Imaging.

[26]  M. Schlumberger,et al.  Strategies of radioiodine ablation in patients with low-risk thyroid cancer. , 2012, The New England journal of medicine.

[27]  J. Shah,et al.  Estimating risk of recurrence in differentiated thyroid cancer after total thyroidectomy and radioactive iodine remnant ablation: using response to therapy variables to modify the initial risk estimates predicted by the new American Thyroid Association staging system. , 2010, Thyroid : official journal of the American Thyroid Association.

[28]  J. Franklyn,et al.  Ablation with low-dose radioiodine and thyrotropin alfa in thyroid cancer. , 2012, The New England journal of medicine.

[29]  S. Larson,et al.  Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. , 2013, The New England journal of medicine.

[30]  O. Schober,et al.  Procedure guideline for radioiodine therapy and 131iodine whole-body scintigraphy in paediatric patients with differentiated thyroid cancer , 2007, Nuklearmedizin.

[31]  M. Medvedec.  Thyroid stunning in vivo and in vitro , 2005, Nuclear medicine communications.